Market News AIOpen the app

CLRB stock news · Cellectar Biosciences

Stories about Cellectar Biosciences (CLRB) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CLRB

Follow Cellectar Biosciences (CLRB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLRB
Free on the App Store and Google Play, or on the web.
  1. Oct 6, 2026, 8:15 AM ET · Market

    12 health care stocks are changing in price before the market opens on Tuesday.

    Neutral

    Cellectar Biosciences' shares rose about 11% to $1.85 per share before Tuesday's market opened. The article gives no company update or reason for the move, so it does not change the business outlook.

  2. Aug 13, 2026, 9:30 AM ET · Results

    Transcript of Cellectar Biosciences' Q2 2026 Earnings Conference Call.

    Good for CLRB

    Cellectar Biosciences' Q2 earnings call highlighted substantial progress in clinical trials and financial backing, which positions the company favorably for future growth and regulatory approvals. The promising results for iopofosine I-131 in treating Waldenström's macroglobulinemia and the completion of a significant financing round are likely to drive investor interest and stock performance.